chromosome

trends & perspectives in clinical research

goBalto Chromosome

Webinar: CRO Consolidation: A Sinister Threat or Windfall for Pharma?

by Craig Morgan
12Mar2018

Save your seat for this upcoming webinar! Is the growth momentum in CRO mergers and acquisitions sustainable? And good for the pharmaceutical industry as a whole?

Webinar: CRO Consolidation: A Sinister Threat or Windfall for Pharma?

Title: CRO Consolidation: A Sinister Threat or Windfall for Pharma?

Description:

Outsourcing has become the popular way for pharmaceutical companies to utilize on-demand services, improving operational efficiencies and therapeutic expertise and adding extensive geographic capabilities. The reflects a sharper focus on core competencies and a shift to allow CROs to manage and conduct clinical trials.

More than just a fad, this trend is nothing less than a paradigm shift in the pharmaceutical industry that has struggled to contain costs and timelines associated with trials as the rescue study services industry has boomed.

But is this growth momentum sustainable? And is CRO M&A good for the pharmaceutical industry as a whole?

In this webinar, we will explore:

  • Recent noteworthy mergers and acquisitions (M&As) in the CRO industry and related eClinical technology providers
  • Benefits for sponsors the M&A trend in the CRO industry provides
  • Drawbacks to consider for sponsors in the M&A trend of CROs and related eClinical technology providers
  • The ramifications of CRO consolidation in study startup, a notorious bottleneck in starting clinical trials and changing role of sponsors in oversight/transparency of operations

This webinar is applicable to:

  • Sponsor and CRO executives and senior management roles responsible for site identification, feasibility assessment, selection and activation
  • Sponsor and CRO executives and senior management roles responsible for clinical research strategy and vendor management

When:

Tuesday, March 27
1 pm ET
10 am PT

Save my seat

Presenters:

Cindy Henderson
CINDY HENDERSON
Executive Vice President, Strategic Development
Veristat
Cindy oversees Clinical Operations as well as Business Development, Proposals & Contracts and Marketing functions at Veristat. With over 20 years of experience, Cindy concentrates on providing innovative functional and operational support to Veristat's diverse, sponsor-based clinical studies. Cindy's key areas of operational expertise include the ability to lend deep insight into the sequence of events clinical studies take as they advance toward the goal of product regulatory submission, the ability to collaborate with sponsor companies in the design of medical product and drug development plans, the ability to effectively manage and assess client needs, and the ability to strategically outline the required resources for clinical programs. Prior to joining Veristat in 2007, Cindy served as the Senior Manager of Training, Innovations and Processes at Averion International Corporation where she led various initiatives to create and improve standard operating procedures, while implementing new technologies for data management. While at PAREXEL International Corporation as the Associate Director of Data Management, Cindy managed several international clinical trials and software development, validation, and implementation efforts.
Carol Aliyar
CAROL ALIYAR
Executive Vice President, Global Site Start Up
Syneos Health
Carol has worked within the Clinical Research Industry for over 25 years and serves as Global Head of Site Start-Up for Syneos Health. Carol is responsible for leading the Company's site start-up efforts, including site start-up operations, site start-up and activation, ethics and regulatory submissions/approval. She has more than two decades of clinical operations experience to her new role, including broad therapeutic expertise and experience in leading large-scale global clinical development programs. Carol is focused on fostering strong site relationships to optimize timelines and deliver rapid site start-up for global clinical trials, establishing the foundation for successful collaboration across the duration of a study.
Barry Milton
BARRY MILTON
Head of Business Operations
Novartis
Barry is a clinical trial and operations management expert. His experiences as an Oncology nurse, clinical trial coordinator and his senior management roles at Novartis, Roche, Merck, and AstraZeneca provides him with a well-rounded set of skills and experiences in the clinical trial space. His passion is transforming study management and trial execution processes through the creation of optimized business processes, which are supported by facilitating systems, which allow sponsor and investigator teams to meet their patient and clinical program goals faster and more efficiently.
Jeff Kasher
JEFF KASHER
President
Patients Can't Wait
Jeff Kasher is a known pharmaceutical development change expert with 28 years of experience at Eli Lilly. He is passionate for improving outcomes, bringing patients and research sites into the development process, and dramatically decreasing time to market. His expertise includes novel product development from bench through market launch, research and clinical trial leadership, innovation center start-up as well as new industry paradigm creation.

Jeff is President of Patients Can't Wait, a member of Advisory Boards for TrialReach, Be the Partner, goBalto, BlueCloud, and ZS Associates. He advises several multinational Pharmaceutical companies and CROs. He sits on the DPharm steering committee and faculty and is a member of Linking Leaders. In 2013, CenterWatch named Jeff one of the "20 Innovators Changing the Face of the Clinical Trials Industry." He received a B.S. in Chemistry from Franklin & Marshall College, a Ph.D. in Pharmacology from the State University of New York, and a Post-Doctoral Fellowship in Physiology at Yale University School of Medicine.

Recent Posts